Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (como fosfato) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agentes antineoplásicos - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi é indicado para o tratamento de pacientes adultos com polycythaemia vera que são resistentes ou intolerantes hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - outras preparações dermatológicas - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

novartis biociencias s.a - fosfato de ruxolitinibe - antineoplasico

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agentes antineoplásicos - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

eurofarma laboratÓrios s.a. - itraconazol - antimicoticos sistemicos

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

aché laboratórios farmacêuticos s.a - acetato de dexametasona, fosfato dissÓdico de dexametasona - glicocorticoides sistemicos

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

prati donaduzzi & cia ltda - itraconazol - antimicoticos sistemicos

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

janssen-cilag farmacÊutica ltda - itraconazol - antimicoticos sistemicos

Ευρωπαϊκή Ένωση - Πορτογαλικά - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agentes antineoplásicos - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Βραζιλία - Πορτογαλικά - ANVISA (Agência Nacional de Vigilância Sanitária)

nova quimica farmacÊutica s/a - itraconazol - antimicotico